Clinical Trials Logo

Clinical Trial Summary

This phase I trial studies the side effects and best dose of pembrolizumab when given together with chemoradiotherapy or radiation therapy in treating patients with small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more cancer cells. Giving pembrolizumab with chemoradiotherapy or radiation therapy may be a better treatment for small cell lung cancer.


Clinical Trial Description

PRIMARY OBJECTIVES: I. Safety of pembrolizumab (MK 3475) plus chemotherapy (chemo)/radiation for limited-stage small-cell lung cancer (LS-SCLC). II. Safety of MK-3475 plus radiation for extensive-stage small-cell lung cancer (ES-SCLC). SECONDARY OBJECTIVES: I. MK-3475 will improve progression free survival (PFS) compared to historical controls for LS-SCLC and ES-SCLC. OUTLINE: This is a dose-escalation study of pembrolizumab. Patients are assigned to either Part A or Part B based on diagnosis. PART A (LS-SCLC): Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1 and undergo radiation therapy twice daily (BID) 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade > 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity. PART B (ES-SCLC): Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, all patients are followed up at 30 days and then every 12 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02402920
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 1
Start date July 22, 2015
Completion date July 31, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04464122 - Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Active, not recruiting NCT03375320 - Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Phase 3
Active, not recruiting NCT03980925 - Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Phase 2
Recruiting NCT02402244 - Project: Every Child for Younger Patients With Cancer
Recruiting NCT05113355 - Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm Phase 2
Recruiting NCT05879055 - A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN Phase 2
Terminated NCT03001349 - 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Early Phase 1
Completed NCT02399215 - Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Phase 2
Recruiting NCT05165407 - Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC Phase 2
Recruiting NCT06337760 - YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
Recruiting NCT04927611 - Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
Active, not recruiting NCT01638533 - Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Phase 1
Recruiting NCT02817945 - Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging Early Phase 1
Active, not recruiting NCT03950609 - Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors Phase 2
Active, not recruiting NCT04750954 - Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors Phase 1
Not yet recruiting NCT04931446 - Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis
Recruiting NCT06343428 - Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
Recruiting NCT04720391 - Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)
Recruiting NCT03734913 - A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT03511768 - A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms Phase 1/Phase 2